Related Experiment Video
Updated: Aug 5, 2026

Photoacoustic Cystography
Published on: June 11, 2013
N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low
V O Gomes1, C E Poli de Figueredo, P Caramori
1Division of Interventional Cardiology, Hospital São Lucas, Pontifícia Universidade Católica-RS, Porto Alegre, Brazil.
Insights
Oral N-acetylcysteine did not prevent contrast-induced nephropathy (CIN) in patients undergoing cardiac procedures. This study found no significant difference in CIN rates between N-acetylcysteine and placebo groups.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a risk following cardiac catheterisation.
- Patients with pre-existing renal risk factors or diabetes are particularly susceptible.
- Ionic low osmolality contrast media are used in cardiac procedures.
Purpose of the Study:
- To evaluate the efficacy of oral N-acetylcysteine in preventing CIN.
- To assess N-acetylcysteine's role in low to moderate risk patients undergoing cardiac catheterisation.
- To compare CIN incidence with and without N-acetylcysteine administration.
Main Methods:
- A multicentre, double-blind, placebo-controlled clinical trial.
- 156 patients with renal risk factors or diabetes were enrolled.
- Patients received either oral N-acetylcysteine (600 mg twice daily for two days) or placebo.
Main Results:
- No significant difference in CIN development between N-acetylcysteine and placebo groups (10.4% vs 10.1%, p=1.00).
- Mean serum creatinine change was comparable in both groups.
- No significant difference in endogenous creatinine clearance changes was observed.
Conclusions:
- Oral N-acetylcysteine does not prevent CIN in low to moderate risk patients.
- The study did not support the use of N-acetylcysteine for CIN prevention in this population.
- Further research may be needed for different patient groups or contrast agents.
Objective:
To evaluate oral N-acetylcysteine in the prevention of contrast induced nephropathy (CIN) in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium.
Methods:
In a multicentre double blind clinical trial 156 patients undergoing coronary angiography or percutaneous coronary intervention with serum creatinine > or = 106.08 micromol/l or creatinine clearance < 50 ml/min or diabetes mellitus were randomly assigned to receive N-acetylcysteine 600 mg orally twice daily for two days or placebo. Only low osmolality ionic contrast medium was used.
Results:
Sixteen patients developed CIN, defined as an increase of 44.2 micromol/l in creatinine in 48 hours: eight of 77 patients (10.4%) in the N-acetylcysteine group and eight of 79 patients (10.1%) in the placebo group (p = 1.00). The mean (SD) change in serum creatinine was similar in both groups: 7.96 (35.36) micromol/l in the N-acetylcysteine group and 6.19 (25.64) micromol/l in the placebo group (p = 0.67). No difference was observed in the change in endogenous creatinine clearance (-0.54 (10.4) ml/min v -2.52 (12.3) ml/min, N-acetylcysteine and placebo, respectively, p = 0.28).
Conclusion:
Oral N-acetylcysteine did not prevent CIN in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium.
More Related Videos
Related Concept Videos
Radiological Investigation I: X-ray and CT
Imaging Studies for Cardiovascular System V: CT
Imaging Studies III: Computed Tomography
Imaging Studies VII: Vascular Imaging
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

